Diabetic Peripheral Neuropathy: Should a Chaperone Accompany Our Therapeutic Approach?
- 10 August 2012
- journal article
- review article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET)
- Vol. 64 (4), 880-900
- https://doi.org/10.1124/pr.111.005314
Abstract
Diabetic peripheral neuropathy (DPN) is a common complication of diabetes that is associated with axonal atrophy, demyelination, blunted regenerative potential, and loss of peripheral nerve fibers. The development and progression of DPN is due in large part to hyperglycemia but is also affected by insulin deficiency and dyslipidemia. Although numerous biochemical mechanisms contribute to DPN, increased oxidative/nitrosative stress and mitochondrial dysfunction seem intimately associated with nerve dysfunction and diminished regenerative capacity. Despite advances in understanding the etiology of DPN, few approved therapies exist for the pharmacological management of painful or insensate DPN. Therefore, identifying novel therapeutic strategies remains paramount. Because DPN does not develop with either temporal or biochemical uniformity, its therapeutic management may benefit from a multifaceted approach that inhibits pathogenic mechanisms, manages inflammation, and increases cytoprotective responses. Finally, exercise has long been recognized as a part of the therapeutic management of diabetes, and exercise can delay and/or prevent the development of painful DPN. This review presents an overview of existing therapies that target both causal and symptomatic features of DPN and discusses the role of up-regulating cytoprotective pathways via modulating molecular chaperones. Overall, it may be unrealistic to expect that a single pharmacologic entity will suffice to ameliorate the multiple symptoms of human DPN. Thus, combinatorial therapies that target causal mechanisms and enhance endogenous reparative capacity may enhance nerve function and improve regeneration in DPN if they converge to decrease oxidative stress, improve mitochondrial bioenergetics, and increase response to trophic factors.Keywords
This publication has 270 references indexed in Scilit:
- Interplay of sorbitol pathway of glucose metabolism, 12/15-lipoxygenase, and mitogen-activated protein kinases in the pathogenesis of diabetic peripheral neuropathyBiochemical Pharmacology, 2012
- Astrocyte targeted overexpression of Hsp72 or SOD2 reduces neuronal vulnerability to forebrain ischemiaGlia, 2010
- Redox regulation of mitochondrial fission, protein misfolding, synaptic damage, and neuronal cell death: potential implications for Alzheimer’s and Parkinson’s diseasesApoptosis, 2010
- 4-Hydroxy-2-Nonenal Induces Mitochondrial Dysfunction and Aberrant Axonal Outgrowth in Adult Sensory Neurons that Mimics Features of Diabetic NeuropathyNeurotoxicity Research, 2009
- Discovery and development of heat shock protein 90 inhibitorsBioorganic & Medicinal Chemistry, 2009
- Neuroprotective activity and evaluation of Hsp90 inhibitors in an immortalized neuronal cell lineBioorganic & Medicinal Chemistry, 2008
- Inducible nitric oxide synthase gene deficiency counteracts multiple manifestations of peripheral neuropathy in a streptozotocin-induced mouse model of diabetesDiabetologia, 2008
- Epidermal nerve fiber quantification in the assessment of diabetic neuropathyActa Histochemica, 2008
- Hyperglycemia and downregulation of caveolin-1 enhance neuregulin-induced demyelinationGlia, 2008
- High prevalence of low plasma thiamine concentration in diabetes linked to a marker of vascular diseaseDiabetologia, 2007